Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 932
-SubTopic 360
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 932
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-10(c)(7)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1

Commitments and Contingencies (Details Narrative)		1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Commitments and Contingencies (Details Narrative)	Jan. 07, 2026 USD ($) shares	Mar. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)	Mar. 17, 2025 shares	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) shares	May 08, 2026 USD ($)	Mar. 31, 2026 EUR (€)	Dec. 31, 2025 EUR (€)	May 15, 2025 USD ($)
Grant repyable					$ 562,862		$ 562,862
Derivative Liability			$ 934,720		2,174,900		2,174,900		$ 934,720
Debt issuance costs							1,103,820
Debt discount net					405,068	$ 325,305	855,202	$ 325,305
Long-term debt					7,051,835		7,051,835
Long-term debt payable					7,051,835		7,051,835
Debt instrument carrying amount										$ 22,500,000
Increase in outstanding principal							240,000	$ 383,333
Aggregate increase in outstanding principal							623,333
Operating Lease Right of Use Obligations [Member]
Cash paid for operating lease, liability							111,891
Operating lease expense							112,699
Short term lease costs							28,961
Two Thousand Twenty Two [Member] \| Univercity Of Texas MD [Member]
Additional cost of company							449,406
Due to related party					0		0
Collaborative obligations amount due					163,545		163,545
August Two Thousand Twenty Three [Member] \| Guy's and St Thomas' NHS Foundation Trust [Member]
Additional cost of company							129,127
Due to related party					21,521		21,521
Payment to related party							129,127
July Thirty One Thousand Twenty Three [Member] \| Xenetic Biosciences Inc and CLS Therapeutics [Member]
Additional cost of company							107,589
Due to related party					0		0
Collaborative obligations amount due					55,305		55,305
VolitionRx [Member] \| In 2016 [Member] \| Long-term Debt [Member]
Maximum borrowing capacity					262,552		262,552
Outstanding principal balance					141,512		$ 141,512
Interest rate							7.32%
Managing Director's Agreement [Member]
Royalty payment							$ 125,581
Royality percentage							6.00%
Royalties payable					223		$ 223
Clinical Study Research Agreement [Member] \| University of Taiwan [Member] \| In 2018 [Member]
Due to related party					510,000		510,000
Payment to related party							510,000
Collaborative obligations amount due					2,550,000		$ 2,550,000
Lease agreement expire period							three-year
Notes Payable [Member]
Convertible promissory note	$ 2,400,000
Proceeds from issuance of debt	$ 1,755,000
Warrant issued to purchase common stock \| shares	350,018
Convertible Notes Payable [Member]
Monthly payment							$ 416,666
Monthly payments							1,000,000
Convertible promissory note													$ 7,500,000
Warrant for purchase common stock							$ 651,042
Stock upon repayment or conversion description							ownership limitation equal to 4.99% of the Company’s outstanding shares of common stock; provided, that if Lind and its affiliates beneficially own in excess of 4.99% of the Company’s outstanding shares of common stock, then such limitation shall automatically increase to 9.99% so long as Lind and its affiliates own in excess of 4.99% of such common stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon Lind and its affiliates ceasing to own in excess of 4.99% of such common stock)
Initial fair value description							(i) dividend yield of 0%; (ii) expected volatility of 91.48%; (iii) risk-free interest rate of 4.23%; (iv) simulated term of 2.0 years; (v) estimated fair value of the common shares of $5.832 per share; and (vi) various probability assumptions.
Derivative Liability					385,300		$ 385,300
Initial fair value							1,297,500
Original issue discount							400,000
Debt issuance costs							245,000
Debt discount net							1,646,152
Gustave Roussy [Member]
Additional cost of company							119,540
Due to related party					34,889		34,889
Payment to related party							84,942
SA Namur Invest Preface [Member] \| Loan Agreement [Member]
Maximum borrowing capacity \| €												€ 650,000
Long-term debt, interest rate			5.00%
Long-term debt, maturity date			September 2
Long-term debt \| €												€ 325,000
Loan principal balance payable			$ 371,035						$ 371,035
Wallonie Entreprendre [Member] \| Loan Agreement [Member]
Maximum borrowing capacity \| €											€ 1,000,000
Long-term debt, interest rate		7.00%
Long-term debt, maturity date		March 2031
Long-term debt \| €											€ 500,000
Loan principal balance payable		$ 570,823
Board of Directors [Member]
Number of RSUs granted \| shares				143,400
RSUs cancelled during period \| shares									100,380
National University of Taiwan Second [Member] \| October Two Thousand Twenty Four [Member]
Additional cost of company							402,250
Due to related party					$ 100,563		100,563
Payment to related party							160,900
Restricted Stock Units [Member] \| One
Share-based compensation arrangement by share-based payment award expense							338,342
Unrecognized compensation expense							145,914
Restricted Stock Units [Member] \| Two
RSU vested in 2026							0
RSU vested in 2027							56,026
RSU vested in 2028							89,888
Restricted Stock Units [Member]
Share-based compensation arrangement by share-based payment award expense							652,359
Unrecognized compensation expense							$ 16,204